Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | CA6 | P23280 | 2/20 | 0.47 |
| ▸ | CA5A | P35218 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990351 | 1.00 | TTR (0.53) | TTRBACE1MAPTALDH1A1MEN1 | |
| SCHEMBL1318274 | 0.92 | CA12 (0.58) | TTRBACE1MAPTALDH1A1MEN1 | |
| SCHEMBL2995317 | 0.92 | CA12 (0.58) | TTRBACE1MAPTALDH1A1MEN1 | |
| SCHEMBL2998925 | 0.92 | KDM4E (0.55) | TTRMAPTALDH1A1KMT2ATDP1 | |
| SCHEMBL2998919 | 0.92 | KDM4E (0.55) | TTRMAPTALDH1A1KMT2ATDP1 | |
| SCHEMBL13704175 | 0.89 | BACE1 (0.53) | TTRBACE1MAPTALDH1A1MEN1 | |
| SCHEMBL2990322 | 0.89 | TTR (0.54) | TTRMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL2990320 | 0.89 | TTR (0.54) | TTRMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL13242591 | 0.85 | MAPT (0.51) | BACE1MAPTMEN1KMT2AMAOB | |
| SCHEMBL2991861 | 0.84 | MAPT (0.47) | TTRMAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179192-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NICOX S.A. (FR) | 2010-07-15 | — | — | US | claimed |
| EP-2167070-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | Nicox S.A. (FR) | 2010-03-31 | — | — | EP | claimed |
| WO-2009007230-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NICOX S.A. (FR) | 2009-01-15 | — | — | WO | claimed |
| US-20100179192-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NICOX S.A. (FR) | 2010-07-15 | — | — | US | disclosed |
| EP-2167070-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | Nicox S.A. (FR) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009007230-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NICOX S.A. (FR) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179192-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NOS1, NOS2, NOS3 | TTR 4432/4885BACE1 2629/4885MAPT 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.